Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01644513 · ClinicalTrials.gov registry record

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

A clinical trial, sponsored by Sequenom.

Completed
Registry status
196
Enrollment target

NCT01644513: Completed study, sponsored by Sequenom.

NCT01644513 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 196 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01644513 has completed, sponsored by Sequenom.

COMPLETED
Registry status
196 participants
Enrollment target

Study Summary

Patients with AMD who are being or have been treated with eye injections of drugs known as anti-VEGF agents with either good or poor response will have DNA collected with check swabs for analysis.

Trial Details

FieldValue
Enrollment Target 196 participants
Start Date 2012-07
Est. Completion 2012-12
Sequenom

26 total trials

What the finished NCT01644513 record still lists

NCT01644513 is an observational study that tracks outcomes without assigning an intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01644513 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01644513 about?

NCT01644513 is a clinical study titled "Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients". Patients with AMD who are being or have been treated with eye injections of drugs known as anti-VEGF agents with either good or poor response will have DNA collected with check swabs for analysis.

What is the current status of trial NCT01644513?

This trial is currently completed. The enrollment target is 196 participants. The study started on 2012-07. Estimated completion is 2012-12.

Who is sponsoring clinical trial NCT01644513?

This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02822768 · 196 participants · NA

    Packing Versus no Packing for Cutaneous Abscess

  • NCT04250259 · 196 participants · Phase 2

    SAMe Trial for Patients With Alcoholic Cirrhosis

  • NCT05142592 · 196 participants · Phase 1

    Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

  • NCT05317832 · 196 participants · Phase 2

    Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01644513, the US trial registry maintained by the National Library of Medicine. NCT01644513 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.